Lesson
Person-Centered Selection and Sequencing
The best glucose-lowering medicine is defined by the goal it must achieve and the risks, burdens, and access constraints it introduces. A1C is one axis within a multidimensional decision.
- Independent treatment goals
- Comorbidity-directed selection
- Efficacy and durability
- Hypoglycemia and weight
- Access and shared decisions
Glucose, ASCVD, heart failure, kidney, weight, liver, or burden
Organ function, adverse effects, hypoglycemia, route, schedule, and access
Efficacy, tolerance, outcome, cost, persistence, and revised goals
Separate treatment objectives
A glucose-lowering plan may need to reduce A1C, protect the kidney, reduce atherosclerotic events, prevent heart-failure hospitalization, improve obesity or metabolic liver disease, avoid hypoglycemia, or reduce burden. These objectives overlap but are not interchangeable. Cardiorenal or weight-directed therapy can be indicated irrespective of current A1C.
Use comorbidity before habit
Established or high-risk ASCVD supports a GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated benefit. Heart failure supports an SGLT2 inhibitor, while symptomatic HFpEF with obesity can also support GLP-1-based therapy with demonstrated benefit. CKD selection incorporates eGFR, albuminuria, glycemic need, and current product or guideline thresholds.
Match efficacy and timing to the gap
Higher-efficacy GLP-1-based therapies and rational combinations are more likely to close a large glycemic gap than a low-efficacy add-on. Initial combination therapy can shorten time above goal. Symptoms of hyperglycemia, catabolism, crisis, A1C above 10 percent, or glucose at least 300 mg/dL can require insulin rather than serial noninsulin escalation.
Make implementation part of selection
Confirm coverage, out-of-pocket cost, supply, route, dexterity, cognition, schedule, food access, gastrointestinal tolerance, monitoring, and willingness. Reassess efficacy, adverse effects, hypoglycemia, burden, and adherence after initiation. A drug that cannot be obtained or continued is not an effective choice.
Quick check
Lesson
Metformin
Metformin remains effective, inexpensive, familiar, and weight neutral or modestly weight lowering, but kidney thresholds, gastrointestinal tolerance, vitamin B12, hypoxic stress, and contrast context determine safe use.
- Hepatic glucose production
- Renal thresholds
- Gastrointestinal titration
- Lactic acidosis risk
- Vitamin B12 and contrast
Reduce fasting glucose without directly forcing insulin secretion
Start low, use meals, and consider extended release when appropriate
Kidney decline, hypoxia, acute illness, and selected contrast exposure
Connect mechanism to the fasting pattern
Metformin primarily reduces hepatic glucose production and improves insulin sensitivity without directly forcing beta-cell insulin release. It therefore has low intrinsic hypoglycemia risk. Immediate-release and extended-release products differ in schedule and gastrointestinal tolerability, and formulations should not be assumed interchangeable milligram for milligram without checking the label.
Start low and titrate with food
Gradual titration reduces nausea, diarrhea, abdominal discomfort, and early discontinuation. Immediate-release metformin is commonly taken with meals, while many extended-release products are taken with the evening meal. A tablet shell can appear in stool with some extended-release systems without representing loss of the dose.
Apply kidney and acute-illness safeguards
Current labeling contraindicates metformin when eGFR is below 30 mL/min/1.73 m2 and does not recommend starting it when eGFR is 30 to 45. If eGFR later falls below 45, reassess benefit and risk. Temporarily interrupt treatment during selected iodinated-contrast studies and clinical states that increase hypoxia, dehydration, hemodynamic instability, or acute kidney injury risk, then restart only after stability and renal function are confirmed.
Monitor what chronic use can change
Long-term therapy can reduce vitamin B12 absorption, so periodic assessment is appropriate when anemia, neuropathy, malabsorption, or prolonged exposure raises concern. Lactic acidosis is rare but serious and is linked to accumulation and major physiologic stress rather than routine mild gastrointestinal symptoms. Education should distinguish common intolerance from emergency symptoms.
Quick check
Lesson
SGLT2 Inhibitors
SGLT2 inhibition changes proximal-tubule glucose and sodium handling. Its glycemic, kidney, and heart-failure effects must be interpreted separately, especially as kidney function declines.
- Glucosuria and natriuresis
- Heart-failure and kidney benefit
- Euglycemic ketoacidosis
- Volume and genitourinary safety
- Procedure interruption
Increase glucosuria and natriuresis through SGLT2 inhibition
Use demonstrated outcome benefit independently from A1C when indicated
Prevent ketoacidosis through ketone awareness and procedure planning
Trace the proximal-tubule mechanism
SGLT2 inhibitors reduce renal glucose and sodium reabsorption, increasing urinary glucose and modest natriuresis. Glucose lowering diminishes as eGFR declines, but kidney and heart-failure benefits can persist within current evidence and labeling. The class has low intrinsic hypoglycemia risk unless paired with insulin or a secretagogue.
Use outcome evidence by indication
An SGLT2 inhibitor is recommended in type 2 diabetes with heart failure, irrespective of A1C. CKD use follows eGFR, albuminuria, progression risk, and the chosen product's indications. Established cardiovascular and kidney benefits are product and population specific, so one class label should not be used as proof for every agent and outcome.
Recognize ketoacidosis without extreme glucose
SGLT2-associated ketoacidosis can occur with glucose below the level expected in classic DKA. Risk rises with insulin deficiency, acute illness, fasting, surgery, low-carbohydrate intake, dehydration, alcohol excess, and insulin dose reduction. Nausea, vomiting, abdominal pain, malaise, or dyspnea require ketone and acid-base assessment even when glucose is not markedly high.
Prevent volume and infection complications
Assess volume status, kidney function, diuretics, blood pressure, and frailty before initiation. Genital mycotic infection is common enough to counsel proactively. Serious urinary infection and necrotizing fasciitis of the perineum are uncommon but urgent. Foot and amputation risk should be reviewed through current product labeling and the individual's vascular, neuropathic, wound, and infection risk.
Pause for fasting and procedures
Withhold empagliflozin and several other agents for at least three days before surgery or procedures with prolonged fasting, and ertugliflozin for at least four days, when possible. Restart only after clinical stability and oral intake return and ketoacidosis risk has resolved. Acute illness may require earlier interruption and direct clinical guidance.
Quick check
Lesson
GLP-1 and Dual GIP/GLP-1 Therapy
GLP-1-based therapy can provide high glycemic efficacy, weight reduction, and selected cardiovascular, kidney, liver, and HFpEF benefits. Product selection and slow titration preserve those benefits through tolerability and safety.
- Glucose-dependent incretin effects
- Weight and outcome benefits
- Dose escalation
- Gastrointestinal and gallbladder safety
- Product-specific administration
Increase glucose-dependent insulin and reduce inappropriate glucagon
Delay gastric emptying to varying degrees and strengthen satiety
Titrate for tolerance and use product-specific cardiovascular or kidney evidence
Connect incretin signaling to clinical effect
GLP-1 receptor agonists enhance glucose-dependent insulin secretion, reduce inappropriate glucagon, slow gastric emptying to varying degrees, and increase satiety. Tirzepatide activates both GIP and GLP-1 receptors. Intrinsic hypoglycemia risk is low, but insulin or secretagogue doses may need reduction when glycemia improves.
Select for more than A1C
High-potency GLP-1 receptor agonists and dual GIP/GLP-1 therapy can produce substantial glucose and weight effects. Selected products have demonstrated cardiovascular, kidney, HFpEF, or metabolic liver benefits in defined populations. Use the evidence and approved indication for the chosen product rather than transferring every outcome across the entire class.
Titrate for durability
Initiation doses are often intended for tolerability rather than full glycemic effect. Increase only after the product-specific interval and delay escalation when nausea, vomiting, poor intake, dehydration, or constipation remains clinically important. Counsel on smaller meals, stopping when full, hydration, and when persistent or severe symptoms require evaluation.
Screen serious and procedural risks
Current semaglutide and tirzepatide labeling includes a boxed warning about thyroid C-cell tumors in rodents and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. Evaluate suspected pancreatitis and gallbladder disease promptly. Severe gastrointestinal disease, dehydration-related kidney injury, diabetic retinopathy progression with rapid glycemic improvement, and aspiration risk around anesthesia require individualized planning.
Teach the exact formulation
Weekly injections, daily injections, and oral semaglutide have different missed-dose, food, water, timing, and device instructions. Pens must never be shared. Delayed gastric emptying can influence oral drug absorption, especially when a medication has a narrow therapeutic window or strict timing. Do not combine a DPP-4 inhibitor with GLP-1-based therapy because added glucose lowering is not meaningful.
Quick check
Lesson
DPP-4 Inhibitors
DPP-4 inhibition prolongs endogenous incretin activity with modest glucose lowering, weight neutrality, low intrinsic hypoglycemia, and important product differences in renal dosing and heart-failure warnings.
- Endogenous incretin preservation
- Renal dose adjustment
- Heart-failure warnings
- Pancreatitis and arthralgia
- Bullous pemphigoid
Extend endogenous GLP-1 and GIP activity with modest glucose lowering
Dose most products by eGFR while linagliptin generally remains unchanged
Heart failure, pancreatitis, arthralgia, hypersensitivity, and blistering disease
Preserve endogenous incretins
DPP-4 inhibitors slow degradation of endogenous GLP-1 and GIP, increasing glucose-dependent insulin secretion and reducing glucagon. Their A1C effect is generally modest, weight effect is neutral, and intrinsic hypoglycemia risk is low. They do not reproduce the pharmacologic exposure, weight reduction, or outcome profile of GLP-1 receptor agonists.
Distinguish products by clearance
Sitagliptin, saxagliptin, and alogliptin require kidney-based dose adjustment, while linagliptin generally does not. Verify the current eGFR and exact product before prescribing. Strong CYP3A4 or P-glycoprotein interactions can alter saxagliptin exposure and required dosing.
Keep heart failure product specific
Heart-failure hospitalization signals led to warnings for saxagliptin and alogliptin. In a person with heart failure, use a class with demonstrated heart-failure benefit rather than choosing DPP-4 inhibition for that objective. Do not assume a neutral glycemic drug is a cardiorenal outcome drug.
Recognize uncommon class safety signals
Pancreatitis, serious hypersensitivity, severe disabling arthralgia, and bullous pemphigoid have been reported. A blistering or erosive eruption requires prompt evaluation and drug review. Reduce insulin or secretagogue exposure when improved glycemia raises hypoglycemia risk.
Quick check
Lesson
Sulfonylureas and Meglitinides
Insulin secretagogues can lower glucose quickly and inexpensively, but they require functioning beta cells and trade that effect for hypoglycemia, weight gain, meal dependence, and limited cardiorenal benefit.
- KATP channel closure
- Sulfonylurea duration
- Meglitinide meal timing
- Hypoglycemia prevention
- Kidney and interaction risk
Stimulate insulin secretion with less dependence on current glucose
Match meglitinides to meals and distinguish longer sulfonylurea action
Reassess dose with kidney decline, low intake, and stronger add-on therapy
Force beta-cell secretion
Sulfonylureas and meglitinides close the beta-cell ATP-sensitive potassium channel and stimulate insulin release with less dependence on current glucose than incretin-based therapy. They therefore can cause hypoglycemia and weight gain. Effectiveness declines as beta-cell reserve diminishes.
Distinguish long and short exposure
Second-generation sulfonylureas include glipizide, glimepiride, and glyburide. Glyburide has active metabolites and a greater prolonged-hypoglycemia concern in kidney impairment and older adults. Meglitinides act more rapidly and briefly and are dosed with meals, so a skipped meal generally means a skipped dose.
Prevent predictable hypoglycemia
Review meal timing, food access, alcohol, exercise, kidney and liver function, cognition, driving, and recognition of low glucose. When adding a more effective therapy, reassess and often reduce or stop the secretagogue. Recurrent hypoglycemia is a reason to change the regimen, not merely to add snacks indefinitely.
Check high-impact interactions
Repaglinide and gemfibrozil should not be combined because exposure and hypoglycemia can rise substantially. Other enzyme inhibitors or inducers can change secretagogue exposure. Beta blockers can alter adrenergic warning symptoms without eliminating every manifestation of hypoglycemia.
Quick check
Lesson
Thiazolidinediones
Thiazolidinediones improve insulin sensitivity through nuclear-receptor signaling and can provide durable glucose lowering, but delayed onset, fluid retention, weight gain, fractures, and heart-failure risk sharply shape selection.
- PPAR-gamma signaling
- Delayed clinical effect
- Fluid retention and heart failure
- Fracture and weight risk
- Pioglitazone-specific cautions
Change gene expression in adipose and insulin-responsive tissue
Assess response over weeks rather than correcting the dose each day
Monitor edema, weight, heart failure, fracture, eye, liver, and bladder risk
Change transcription, not acute secretion
Pioglitazone activates PPAR-gamma and changes gene transcription related to adipocyte function and insulin sensitivity. It does not directly trigger insulin release and has low intrinsic hypoglycemia risk. Because the mechanism is transcriptional, full glucose effect develops over weeks rather than hours.
Treat fluid retention as a mechanism
Thiazolidinediones can cause sodium and fluid retention, edema, weight gain, and new or worsening heart failure. Product labeling carries a boxed heart-failure warning, and initiation is contraindicated in NYHA class III or IV heart failure. Dyspnea, rapid weight gain, orthopnea, or edema requires prompt reassessment rather than automatic diuretic escalation around the culprit.
Screen long-term harms
Fracture risk, particularly in women, macular edema, hepatic injury, and weight gain influence selection and follow-up. Pioglitazone labeling advises against use in active bladder cancer and requires careful benefit-risk consideration with prior bladder cancer. Improved insulin sensitivity can restore ovulation in some anovulatory patients, so reproductive counseling may be relevant.
Use selected benefits without overgeneralizing
Pioglitazone may be useful in selected people with metabolic liver disease or prior cerebrovascular risk based on the applicable evidence and full clinical context. These potential benefits do not erase fluid, fracture, weight, or bladder concerns. Review concurrent insulin because edema and heart-failure risk can increase.
Quick check
Lesson
Alpha-Glucosidase Inhibitors, Pramlintide, and Other Agents
Less frequently used agents remain valuable when their narrow mechanism, dosage form, adverse-effect profile, and cost match a specific need. Their practical instructions often determine success.
- Alpha-glucosidase inhibition
- Pramlintide and mealtime insulin
- Colesevelam
- Bromocriptine-QR
- Mechanism-specific counseling
Delay carbohydrate absorption with the first bite of a meal
Pair pramlintide with reduced mealtime insulin and intensive monitoring
Fit colesevelam or bromocriptine-QR to a defined goal and burden
Delay carbohydrate absorption
Acarbose and miglitol inhibit intestinal alpha-glucosidases and blunt postprandial glucose when taken with the first bite of each main meal. Gas, abdominal discomfort, and diarrhea limit use. If hypoglycemia occurs from concomitant insulin or a secretagogue, treat with glucose rather than relying on sucrose, whose breakdown is delayed.
Replace the amylin signal
Pramlintide slows gastric emptying, suppresses postprandial glucagon, and increases satiety in people already using mealtime insulin. Initiation requires a 50 percent reduction in mealtime insulin, frequent glucose monitoring, and careful retitration. It is injected separately from insulin and is contraindicated in confirmed gastroparesis and hypoglycemia unawareness.
Use colesevelam for a narrow combined goal
Colesevelam can produce modest glucose and LDL lowering but can worsen triglycerides, cause constipation, and bind other medicines. Review triglycerides, bowel disease, swallowing, pill burden, and administration spacing. It is not a substitute for therapies with established high-efficacy glucose or cardiorenal outcomes.
Fit bromocriptine-QR to its schedule and risks
Quick-release bromocriptine is taken in the morning shortly after waking and produces modest glucose lowering through central dopaminergic mechanisms that are not fully defined. Nausea, dizziness, orthostatic hypotension, syncope, psychiatric context, and drug interactions shape use. The diabetes formulation and schedule should not be confused with other bromocriptine products.
Quick check
Lesson
Cardiorenal, Weight, Liver, and HFpEF Integration
Modern type 2 diabetes pharmacotherapy treats organs and outcomes directly. A near-target A1C does not remove an indication for evidence-based cardiovascular, kidney, heart-failure, weight, or liver treatment.
- ASCVD risk reduction
- Heart failure
- CKD
- Obesity and HFpEF
- MASLD and MASH
Use a GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated benefit
Prioritize SGLT2 inhibition and layer product-specific evidence
Choose high-efficacy therapy when obesity or metabolic liver disease is a goal
Treat ASCVD risk irrespective of A1C
In established or high-risk ASCVD, include a GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated cardiovascular benefit. Selection still considers kidney function, heart failure, weight, adverse effects, route, and access. Glucose lowering does not replace statin, blood-pressure, tobacco, antiplatelet, nutrition, or activity care.
Use SGLT2 inhibition for heart failure
Type 2 diabetes with heart failure, whether reduced or preserved ejection fraction, supports an SGLT2 inhibitor to reduce heart-failure hospitalization irrespective of A1C. Assess volume status and diuretic context. In obesity with symptomatic HFpEF, selected dual GIP/GLP-1 or GLP-1 therapy with demonstrated symptom or event benefit can address an additional mechanism.
Preserve kidney function as its own goal
CKD treatment selection incorporates eGFR, albuminuria, progression risk, potassium, blood pressure, and existing renin-angiotensin and mineralocorticoid therapy. SGLT2 and selected GLP-1 receptor agonist benefits can extend beyond glucose. Glycemic efficacy and kidney outcome efficacy should not be assumed to decline in parallel.
Treat weight and liver disease intentionally
Weight is a distinct treatment outcome. High-potency GLP-1-based therapies can support substantial weight reduction when access and tolerability permit. MASLD or MASH can influence selection toward therapies with applicable evidence, but diagnosis, fibrosis risk, nutrition, physical activity, lipid care, and specialist involvement remain necessary.
Quick check
Lesson
Combination Strategy, Deintensification, and Special Settings
A regimen should contain complementary mechanisms with a reason for every medicine. Initiation, escalation, simplification, fasting, procedures, acute illness, and transitions all require active medication reconciliation.
- Rational combination
- Redundant therapy
- Hypoglycemia reduction
- Procedure and illness planning
- Cost and deintensification
Close the efficacy gap with mechanisms and outcomes that complement
Plan for fasting, procedures, illness, contrast, dehydration, and missed meals
Remove redundancy, hypoglycemia, cost, intolerance, and low-value burden
Combine complementary mechanisms
Initial or early combination therapy can improve time to goal when one agent is unlikely to provide enough efficacy. Favor combinations that address independent glucose and outcome needs without duplicating the same pathway. Fixed-dose products can reduce pill burden but can also make titration, interruption, cost, and culprit identification harder.
Remove mechanistic redundancy
Do not combine a DPP-4 inhibitor with a GLP-1 receptor agonist or dual GIP/GLP-1 therapy because meaningful added glucose lowering is absent. When adding an effective low-hypoglycemia therapy, reassess sulfonylurea, meglitinide, and insulin doses rather than stacking every prior medicine indefinitely.
Plan for fasting, illness, and procedures
Use a written plan for SGLT2 interruption, GLP-1-related anesthesia risk, metformin contrast or acute-illness interruption, secretagogue meal dependence, hydration, ketone assessment, and the point at which insulin or emergency care is required. Restarting should follow recovered intake, kidney function, hemodynamic stability, and product-specific guidance.
Deintensify deliberately
Reduce or stop therapy when ineffectiveness, hypoglycemia, intolerance, contraindication, cost, burden, weight loss, organ decline, or revised goals change the benefit-risk balance. Preferentially remove agents that add harm or burden without cardiovascular, kidney, weight, liver, or glycemic benefit needed by that person. Document the new goal and monitoring plan.
Know when noninsulin escalation has ended
Symptoms of hyperglycemia, catabolism, crisis, or very high A1C or glucose can require insulin. Postoperative, critical illness, and selected transplant settings also favor insulin because it is rapidly titratable. Adding another modest oral agent should not delay treatment of severe insulin deficiency or metabolic decompensation.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.